Insys Litigation Documents
In 2016, former executives and managers of Insys Therapeutics Inc. (an opioid manufacturer which produced Subsys, a fentanyl-based pain medication) were indicted by a Grand Jury on charges including conspiracy to commit racketeering, mail and wire fraud, and conspiracy to violate the anti-kickback law in relation to a nationwide conspiracy to bribe medical practitioners and defraud insurers.
The resulting federal trial alleged Dr John Kapoor, the founder of Insys Therapeutics, and his co-defendants, had paid doctors to prescribe its potent opioid medication and then lied to insurance companies to ensure that the expensive painkiller would be covered.
The trial resulted in the conviction of Kapoor, as well as the company’s vice president of managed markets, national director of sales, and two Insys regional sales directors. Kapoor became the first opioid CEO to be sentenced to prison.
In 2019 Insys agreed to a $225 million settlement
to resolve federal criminal and civil cases against the company. Insys filed for Chapter 11 bankruptcy in June 2019, and was the first opioid company to seek bankruptcy protection as a result of legal action related to the opioid crisis. The company’s bankruptcy plan
was approved in U.S. Bankruptcy Court in Wilmington, Delaware in January 2020.
The documents in this collection come from U.S. District Court records (District of Massachusetts, Boston) and from investigation by the New York State Office of the Attorney General.
Documents include: 45 volumes of transcripts from the trial; internal sales training materials, sales rep data, and compensation strategies; submissions to regulatory agencies regarding consumer guides, brochures, and prescribing information; graphics designs for product packaging and labeling; brochures and prescribing publications intended for physicians and the general public; advertisements and marketing materials; correspondence with physicians who were part of the Insys "Speakers Bureau
" paid to give presentations on behalf of the company; and other internal documents.
Date Range: 2000-2019
Where to Start...
Access Insys Therapeutics at a Glance in our Research Tools area for topic/subject guides, an annotated bibliography and a more in-depth overview of the documents.
- Fueling an Epidemic: Inside the Insys Strategy for Boosting Fentanyl Sales, December, 2015. US Senate HSGAC Report. n.d.
- Press release from the NY State Office of the Attorney General. February 1, 2018.
- Insys Files For Chapter 11, Days After Landmark Opioid Settlement Of $225 Million. By Vanessa Romo, NPR, June 10, 2019.
- Opioid Maker Insys Wins Court Approval of Bankruptcy Plan. By Peg Brickley, Wall Street Journal, January 16, 2020.